- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CCR9/ CC-CKR-9/ CDw199 monoclonal antibody
Anti-CCR9/ CC-CKR-9/ CDw199 antibody for FACS & in-vivo assay
Go to CCR9/CCR9 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T97873-Ab-1/ GM-Tg-hg-T97873-Ab-2 | Anti-Human CCR9 monoclonal antibody | Human |
| GM-Tg-rg-T97873-Ab-1/ GM-Tg-rg-T97873-Ab-2 | Anti-Rat CCR9 monoclonal antibody | Rat |
| GM-Tg-mg-T97873-Ab-1/ GM-Tg-mg-T97873-Ab-2 | Anti-Mouse CCR9 monoclonal antibody | Mouse |
| GM-Tg-cynog-T97873-Ab-1/ GM-Tg-cynog-T97873-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CCR9 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T97873-Ab-1/ GM-Tg-felg-T97873-Ab-2 | Anti-Feline CCR9 monoclonal antibody | Feline |
| GM-Tg-cang-T97873-Ab-1/ GM-Tg-cang-T97873-Ab-2 | Anti-Canine CCR9 monoclonal antibody | Canine |
| GM-Tg-bovg-T97873-Ab-1/ GM-Tg-bovg-T97873-Ab-2 | Anti-Bovine CCR9 monoclonal antibody | Bovine |
| GM-Tg-equg-T97873-Ab-1/ GM-Tg-equg-T97873-Ab-2 | Anti-Equine CCR9 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T97873-Ab-1/ GM-Tg-hg-T97873-Ab-2; GM-Tg-rg-T97873-Ab-1/ GM-Tg-rg-T97873-Ab-2; GM-Tg-mg-T97873-Ab-1/ GM-Tg-mg-T97873-Ab-2; GM-Tg-cynog-T97873-Ab-1/ GM-Tg-cynog-T97873-Ab-2; GM-Tg-felg-T97873-Ab-1/ GM-Tg-felg-T97873-Ab-2; GM-Tg-cang-T97873-Ab-1/ GM-Tg-cang-T97873-Ab-2; GM-Tg-bovg-T97873-Ab-1/ GM-Tg-bovg-T97873-Ab-2; GM-Tg-equg-T97873-Ab-1/ GM-Tg-equg-T97873-Ab-2 |
| Products Name | Anti-CCR9 monoclonal antibody |
| Format | mab |
| Target Name | CCR9 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CCR9 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species CCR9/ CC-CKR-9/ CDw199 VLP (virus-like particle) (Products Developing) |
| Cytokine | GM-Tg-g-T97873-Ag-1 | chemokine (C-C motif) receptor 9 (CCR9) protein |
| ORF Viral Vector | vGMLV000052 | human CCR9 Lentivirus particle |
| ORF Viral Vector | pGMLV000052 | human CCR9 Lentivirus plasmid |
| ORF Viral Vector | pGMLPm001974 | mouse Ccr9 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm001974 | mouse Ccr9 Lentivirus particle |
Target information
| Target ID | GM-T97873 |
| Target Name | CCR9 |
| Gene ID | 10803,12769,282832,713934,484793,101083247,530951,100065535 |
| Gene Symbol and Synonyms | A130091K22Rik,CC-CKR-9,CCR9,CDw199,Cmkbr10,GPR-9-6,GPR28 |
| Uniprot Accession | P51686 |
| Uniprot Entry Name | CCR9_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, Immuno-oncology Target, Cytokine Target |
| Disease | N/A |
| Gene Ensembl | ENSG00000173585 |
| Target Classification | Checkpoint-Immuno Oncology, GPCR |
The target: CCR9, gene name: CCR9, also named as CC-CKR-9, CDw199, GPR-9-6, GPR28. The protein encoded by this gene is a G protein-coupled receptor with seven transmembrane domains that belongs to the beta chemokine receptor family. Chemokines and their receptors are key regulators of thymocyte migration and maturation in normal and inflammation conditions. This gene is differentially expressed in T lymphocytes of the small intestine and colon, and its interaction with chemokine 25 contributes to intestinal intra-epithelial lymphocyte homing to the small intestine. This suggests a role for this gene in directing immune responses to different segments of the gastrointestinal tract. This gene and its exclusive ligand, chemokine 25, are overexpressed in a variety of malignant tumors and are closely associated with tumor proliferation, apoptosis, invasion, migration and drug resistance. This gene maps to the chemokine receptor gene cluster. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
